Citations

Clear

382 citation(s) found for "Shapiro, R".

Phase 1/2 study of eprenetapopt (APR-246) in combination with pembrolizumab in patients with solid tumor malignancies.
Starr, Jason S. , Furqan, Muhammad , Ahrorov, Afzal, Hickman, Denice , Gubits, Amy, Attar, Eyal C. , Park, Haeseong , Dumbrava, Ecaterina E. , Mahipal, Amit , Gao, Xin Yuan , Shapiro, Geoffrey I. , Singh, Parminder Pal , Ahrorov, Afzal, Awad, Mark M. , Das, Satya Narayan

Mayo Clinic

Journal of Clinical Oncology | June 2, 2021 | Volume: 39 | Issue: 15_suppl | Pages: TPS3161-TPS3161

10.1200/jco.2021.39.15_suppl.tps3161 Get It

TPS3161 Background: The p53 pathway has been implicated in antitumor immunity, including antigen presentation and T-cell proliferation. Loss of p53 function can increase resistance to immunotherapy across many tumor types. Eprenetapopt (eprenet) is a small molecule that stabilizes the folded structure of p53, resulting in activation of mutant p53 and stabilization of wild-type (WT) p53. It also targets the cellular redox homeostasis, resulting in induction of apoptosis in tumor cells. In vivo, mice carrying supernumerary copies of the TP53 gene harbor a pro-inflammatory tumor microenvironment, an effect recapitulated in TP53 normal-copy mice treated with eprenetapopt. Combining eprenetapopt and anti-PD1 or anti-CTLA4 therapy resulted in enhanced tumor growth inhibition and improved survival in TP53 WT mice inoculated with B16 melanoma and MC38 colon adenocarcinoma cells . Based on these results, we hypothesized that eprenet-induced p53 stabilization may augment response to immunotherapy. To test this hypothesis, we are conducting a phase 1b/2 study of eprenet in combination with pembrolizumab (eprenet+pembro) in pts with solid tumors. Methods: The primary objectives are to determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) and to assess the safety and tolerability of eprenet+pembro in pts with advanced solid tumors. The secondary objectives are to estimate the anti-tumor activity and to describe the pharmacokinetics of the combination. Exploratory objectives include assessing predictive and pharmacodynamic markers of response. The study includes a safety lead-in with a 3+3 dose de-escalation design for pts with advanced solid tumors with known tumor TP53 mutation status ( TP53 WT is acceptable) (max 18 pts), followed by expansion cohorts in pts with NSCLC, gastric/GEJ and urothelial cancer (max 100 pts). In expansion, pts with urothelial and gastric cancers must be naïve to anti-PD-1/ L1 therapy. Eprenet is given IV once daily on Days 1–4 while pembro is administered on Day 3 of each 21-day cycle. The RP2D of eprenet+pembro is considered the dose at which ≤ 1 of 6 pts in a cohort has a dose-limiting toxicity (DLT). Primary endpoints are occurrence of DLTs, adverse events (AEs) and serious AEs with eprenet+pembro. Key secondary endpoints are best objective response, progression free survival and overall survival. Exploratory endpoints include gene mutations by next generation sequencing (including TP53), mRNA expression, multiplex immunohistochemistry and transcriptomics, multiplex flow cytometry on peripheral blood mononuclear cells and cytokines in serum. Continuous monitoring of toxicity will be conducted. The trial opened in May 2020 and is actively enrolling patients. Clinical trial information: NCT04383938.
ST8Sia6 Promotes Tumor Growth in Mice by Inhibiting Immune Responses
Friedman, David J. , Crotts, Sydney B. , Shapiro, Michael J. , Rajcula, Matthew, McCue, Shaylene , Khazaie, Khashayarsha , Dong, Haidong , Shapiro, Virginia Smith , Dong, Haidong , Shapiro, Virginia S , Friedman, David , Shapiro, Michael Jeremy , Liu, Xin

Mayo Clinic

Cancer Immunology Research | June 1, 2021 | Volume: 9 | Issue: 8 | Pages: 952-966

10.1158/2326-6066.cir-20-0834 | PMID 34074677 Get It

Abstract Many tumors exhibit increased incorporation of sialic acids into cell-surface glycans, which impact the tumor microenvironment. Sialic acid immunoglobulin-like lectins (Siglec) are receptors that recognize sialic acids and modulate immune responses, including responses to tumors. However, the roles of individual sialyltransferases in tumorigenesis and tumor growth are not well understood. Here, we examined the sialyltransferase ST8Sia6, which generated α2,8-linked disialic acids that bind to murine Siglec-E and human Siglec-7 and -9. Increased ST8Sia6 expression was found on many human tumors and associated with decreased survival in several cancers, including colon cancer. Because of this, we engineered MC38 and B16-F10 tumor lines to express ST8Sia6. ST8Sia6-expressing MC38 and B16-F10 tumors exhibited faster growth and led to decreased survival, which required host Siglec-E. ST8Sia6 expression on tumors also altered macrophage polarization toward M2, including upregulation of the immune modulator arginase, which also required Siglec-E. ST8Sia6 also accelerated tumorigenesis in a genetically engineered, spontaneous murine model of colon cancer, decreasing survival from approximately 6 months to 67 days. Thus, ST8Sia6 expression on tumors inhibits antitumor immune responses to accelerate tumor growth.
Natural History of Patients With Ischemia and No Obstructive Coronary Artery Disease
Reynolds, Harmony R. , Picard, Michael H. , Spertus, John A. , Peteiro, Jesús , López‐Sendón, José , Senior, Roxy , El‐Hajjar, Mohammad , Čelutkienė, Jelena , Shapiro, Michael D. , Pellikka, Patricia A. , Kunichoff, Dennis , Anthopolos, Rebecca , Abdul-Nour, Khaled, Khouri, Michel G. , Берштейн, Л. Л. , Beltrame, John F. , Min, James K. , Fleg, Jerome L. , Li, Yi , Hochman, Judith S. , Lopez Sendon, Jose Luis , Bershtein, Leonid , Beltrame, John F , Hochman, Judith S , Pellikka, Patricia A , Peteiro, Jesus , Spertus, John A , Shapiro, Michael D , Celutkiene, Jelena , Reynolds, Harmony R , Alfakih, Khaled , Belder, Mark de , Poh, Kian Keong , Maron, David J.

Mayo Clinic

Circulation | June 1, 2021 | Volume: 144 | Issue: 13 | Pages: 1008-1023

10.1161/circulationaha.120.046791 | PMID 34058845 Get It

Background: Ischemia with no obstructive coronary artery disease (INOCA) is common and has an adverse prognosis. We set out to describe the natural history of symptoms and ischemia in INOCA. Methods: CIAO-ISCHEMIA (Changes in Ischemia and Angina over One Year in ISCHEMIA Trial Screen Failures With INOCA) was an international cohort study conducted from 2014 to 2019 involving angina assessments (Seattle Angina Questionnaire) and stress echocardiograms 1 year apart. This was an ancillary study that included patients with a history of angina who were not randomly assigned in the ISCHEMIA trial. Stress-induced wall motion abnormalities were determined by an echocardiographic core laboratory blinded to symptoms, coronary artery disease status, and test timing. Medical therapy was at the discretion of treating physicians. The primary outcome was the correlation between the changes in the Seattle Angina Questionnaire angina frequency score and changes in echocardiographic ischemia. We also analyzed predictors of 1-year changes in both angina and ischemia, and we compared CIAO participants with ISCHEMIA participants with obstructive coronary artery disease who had stress echocardiography before enrollment, as CIAO participants did. Results: INOCA participants in CIAO were more often female (66% of 208 versus 26% of 865 ISCHEMIA participants with obstructive coronary artery disease, P <0.001), but the magnitude of ischemia was similar (median 4 ischemic segments [interquartile range, 3–5] both groups). Ischemia and angina were not significantly correlated at enrollment in CIAO ( P =0.46) or ISCHEMIA stress echocardiography participants ( P =0.35). At 1 year, the stress echocardiogram was normal in half of CIAO participants, and 23% had moderate or severe ischemia (≥3 ischemic segments). Angina improved in 43% and worsened in 14%. Change in ischemia over 1 year was not significantly correlated with change in angina (ρ=0.029). Conclusions: Improvement in ischemia and angina were common in INOCA but not correlated. Our INOCA cohort had a degree of inducible wall motion abnormalities similar to concurrently enrolled ISCHEMIA participants with obstructive coronary artery disease. Our results highlight the complex nature of INOCA pathophysiology and the multifactorial nature of angina. Registration: URL: https://www.clinicaltrials.gov . Unique identifier: NCT02347215.
Complications Following Biologic Therapeutic Injections: A Multicenter Case Series
Eliasberg, Claire D. , Nemirov, Daniel , Mandelbaum, Bert R. , Pearle, Andrew D. , Tokish, John M. , Baria, Michael R. , Millett, Peter J. , Millett, Peter J , Shapiro, Shane A. , Rodeo, Scott A.

Mayo Clinic

Arthroscopy | April 17, 2021 | Volume: 37 | Issue: 8 | Pages: 2600-2605

10.1016/j.arthro.2021.03.065 | PMID 33872744 Get It

Purpose To describe the complications that occur following biologic therapeutic injections. Methods We queried physician members of the Biologic Association, a multidisciplinary organization dedicated to providing a unified voice for all matters related to musculoskeletal biologics and regenerative medicine. Patients included in this study must have (1) received a biologic injection, (2) sustained an adverse reaction, and (3) had a minimum of 1‐year follow‐up after the injection. Patient demographic information, medical comorbidities, diagnoses, and previous treatments were recorded. The type of injection, injection setting, injection manufacturers, and specific details about the complication and outcome were collected. Results In total, 14 patients were identified across 6 institutions in the United States (mean age 63 years, range: 36‐83 years). The most common injections in this series were intra‐articular knee injections (50%), followed intra‐articular shoulder injections (21.4%). The most common underlying diagnosis was osteoarthritis (78.5%). Types of injections included umbilical cord blood, platelet‐rich plasma, bone marrow aspirate concentrate, placental tissue, and unspecified “stem cell” injections. Complications included infection (50%), suspected sterile inflammatory response (42.9%), and a combination of both (7.1%). The most common pathogen identified from infection cases was Escherichia coli (n = 4). All patients who had isolated infections underwent treatment with at least one subsequent surgical intervention (mean: 3.6, range: 1‐12) and intravenous antibiotic therapy. Conclusions This study demonstrates that serious complications can occur following treatment with biologic injections, including infections requiring multiple surgical procedures and inflammatory reactions. Level of Evidence Level IV, case series.
NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 2.2021
Ettinger, David S. , Wood, Douglas E. , Aisner, Dara L. , Akerley, Wallace , Bauman, Jessica R. , Bruno, Débora S. , Chirieac, Lucian R. , D’Amico, Thomas A., Dilling, Thomas J. , Dowell, Jonathan E. , Gettinger, Scott , Gubens, Matthew A. , Hegde, Aparna , Hennon, Mark, Lackner, Rudy P., Leal, Ticiana , Lin, Jules , Martins, Renato , Morgensztern, Daniel , Ng, Thomas, Otterson, Gregory A. , Patel, Sandip Pravin , Riely, Gregory J. , Shapiro, Theresa A. , Singh, Aditi P. , Stevenson, James, Tam, Alda L. , Yang, Stephen C. , Gregory, Kristina M., Hughes, Miranda, Schild, Steven E. , Bharat, Ankit , Chang, Joe Y. , Lanuti, Michael D. , Loo, Billy W. , Lovly, Christine Marie , Massarelli, Erminia , Yanagawa, Jane

Mayo Clinic

Journal of the National Comprehensive Cancer Network | March 5, 2021 | Volume: 19 | Issue: 3 | Pages: 254-266

10.6004/jnccn.2021.0013 | PMID 33668021 Get It

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non–Small Cell Lung Cancer (NSCLC) address all aspects of management for NSCLC. These NCCN Guidelines Insights focus on recent updates to the NCCN Guidelines regarding targeted therapies, immunotherapies, and their respective biomarkers.
Physician Workflow in Two Distinctive Emergency Departments: An Observational Study
Patel, Vimla L., Denton, Courtney A., Traub, Stephen J., Shapiro, Jason S. , Soni, Hiral , Kannampallil, Thomas

Mayo Clinic

Applied Clinical Informatics | March 4, 2021 | Volume: 12 | Issue: 01 | Pages: 141-152

10.1055/s-0040-1722615 | PMID 33657633 Get It

Abstract Objectives We characterize physician workflow in two distinctive emergency departments (ED). Physician practices mediated by electronic health records (EHR) are explored within the context of organizational complexity for the delivery of care. Methods Two urban clinical sites, including an academic teaching ED, were selected. Fourteen physicians were recruited. Overall, 62 hours of direct clinical observations were conducted characterizing clinical activities (EHR use, team communication, and patient care). Data were analyzed using qualitative open-coding techniques and descriptive statistics. Timeline belts were used to represent temporal events. Results At site 1, physicians, engaged in more team communication, followed by direct patient care. Although physicians spent 61% of their clinical time at workstations, only 25% was spent on the EHR, primarily for clinical documentation and review. Site 2 physicians engaged primarily in direct patient care spending 52% of their time at a workstation, and 31% dedicated to EHRs, focused on chart review. At site 1, physicians showed nonlinear complex workflow patterns with a greater frequency of multitasking and interruptions, resulting in workflow fragmentation. In comparison, at site 2, a less complex environment with a unique patient assignment system, resulting in a more linear workflow pattern. Conclusion The nature of the clinical practice and EHR-mediated workflow reflects the ED work practices. Physicians in more complex organizations may be less efficient because of the fragmented workflow. However, these effects can be mitigated by effort distribution through team communication, which affords inherent safety checks.
Association of co-occurring gene alterations and clinical activity of rucaparib in patients with BRCA1 or BRCA2 mutated (BRCA+) metastatic castration-resistant prostate cancer (mCRPC).
Abida, Wassim , Campbell, David , Shapiro, Jeremy , McDermott, Raymond S., Bambury, Richard , Voog, Éric , Zhang, Jingsong , Ryan, Charles J. , Merseburger, Axel S. , Fizazi, Karim , Despain, Darrin , Loehr, Andrea , Dowson, Melanie, Golsorkhi, Tony, Chowdhury, Simon, Patnaik, Akash , Bryce, Alan H. , McDermott, Raymond S., Sautois, Brieuc , Vogelzang, Nicholas J. , Piulats, Josep M.

Mayo Clinic

Journal of Clinical Oncology | March 2, 2021 | Volume: 39 | Issue: 6_suppl | Pages: 80-80

10.1200/jco.2021.39.6_suppl.80 Get It

80 Background: The poly(ADP-ribose) polymerase (PARP) inhibitor rucaparib was granted accelerated approval by the US Food and Drug Administration for patients with BRCA+ mCRPC based on results from the phase 2 TRITON2 study (NCT02952534). The TP53 tumor suppressor gene is among the most frequently mutated genes in human cancers, including mCRPC, and alterations in TP53, PTEN, and RB1 are associated with poor prognosis in patients with prostate cancer and other tumor types. We present data on co-occurring alterations in patients with BRCA+ mCRPC treated with rucaparib in TRITON2. Methods: Patients had progressed on 1–2 lines of androgen receptor-directed therapy and 1 taxane-based chemotherapy and were treated with rucaparib 600 mg BID. Tissue and/or cell-free DNA extracted from plasma samples were profiled comprehensively for genomic alterations using Foundation Medicine, Inc., next-generation sequencing assays. Objective response rate (ORR) was assessed per modified Response Evaluation Criteria in Solid Tumors and Prostate Cancer Working Group 3 criteria by independent radiologic review of patients with measurable disease. Prostate-specific antigen (PSA) response rate (≥50% decrease from baseline) was assessed in all patients. Results: Tissue and/or plasma samples were available for 114/115 patients with BRCA+ mCRPC (visit cutoff date: Dec. 23, 2019). Among patients with BRCA+ mCRPC who had samples available for comprehensive genomic profiling, 36.8% (42/114) had a co-occurring alteration in TP53. Deleterious alterations in PTEN were observed in 34.2% (39/114) of patients, 44% (17/39) of which were homozygous deletions of PTEN. RB1 loss was observed in 12.3% (14/114) of patients and was seen more frequently in patients with measurable disease (18.0%, 11/61) than in patients with non-measurable disease (5.7%, 3/53). Although patients with and without TP53 mutations had generally similar baseline demographics and disease characteristics, visceral disease was more prevalent in patients with TP53 mutations (54.8%; 23/42) than in those without them (29.2%; 21/72). Similar ORR and PSA response rates were seen in patients with BRCA+ mCRPC with or without TP53 mutation, with a non-significant trend towards lower response rates in patients with co-occurring TP53 alterations. Conclusions: Results from TRITON2 showed antitumor activity for rucaparib in patients with BRCA+ mCRPC associated with or without co-occurring alterations in TP53. Demographics and additional efficacy analyses in genomic subgroups with co-occurring alterations in TP53, PTEN, and RB1 will be reported. Clinical trial information: NCT02952534. [Table: see text]
Identification and characterization of the antigen recognized by the germ cell mAb TRA98 using a human comprehensive wet protein array
Fukuda, Eriko , Tanaka, Hiromitsu , Yamaguchi, Kei, Takasaka, Mieko, Kawamura, Yoshifumi , Isotani, Ayako , Tsuchida, Junji, Okada, Yuki , Tsujimura, Akira , Miyagawa, Yasushi, Fukuhara, Shinichiro , Kawakami, Y., Wada, Morimasa, Nishimune, Yoshitake, Goshima, Naoki , Shapiro, Virginia Smith , Okuda, Hidenobu, Ikawa, Masahito

Mayo Clinic

Genes to Cells | February 3, 2021 | Volume: 26 | Issue: 3 | Pages: 180-189

10.1111/gtc.12832 | PMID 33527666 Get It

AbstractTRA98 is a rat monoclonal antibody (mAb) which recognizes a specific antigen in the nuclei of germ cells. mAb TRA98 has been used to understand the mechanism of germ cell development and differentiation in many studies. In mice, the antigen recognized by mAb TRA98 or GCNA1 has been reported to be a GCNA gene product, but despite the demonstration of the immunoreactivity of this mAb in human testis and sperm in 1997, the antigen in humans remains unknown, as of date. To identify the human antigen recognized by mAb TRA98, a human comprehensive wet protein array was developed containing 19,446 proteins derived from human cDNAs. Using this array, it was found that the antigen of mAb TRA98 is not a GCNA gene product, but nuclear factor‐κB activating protein (NKAP). In mice, mAb TRA98 recognized both the GCNA gene product and NKAP. Furthermore, conditional knockout of Nkap in mice revealed a phenotype of Sertoli cell‐only syndrome. Although NKAP is a ubiquitously expressed protein, NKAP recognized by mAb TRA98 in mouse testis was SUMOylated. These results suggest that NKAP undergoes modifications, such as SUMOylation in the testis, and plays an important role in spermatogenesis.
MRS SOFIA: a multicenter retrospective study for use of Sofia for revascularization of acute ischemic stroke
Brinjikji, Waleed , Raz, Eytan , Leacy, Reade De , Meila, Dan , Samaniego, Edgar A. , Shapiro, Maksim , Bageac, Devin , Varon, Alberto , Ren, Zeguang , Rinaldo, Lorenzo , Cloft, Harry J. , De Leacy, Reade , Samaniego, Edgar A , Shapiro, Maksim , Rinaldo, Lorenzo , Mokin, Maxim

Mayo Clinic

Journal of NeuroInterventional Surgery | February 1, 2021 | Volume: 14 | Issue: 1 | Pages: neurintsurg-2020-017042

10.1136/neurintsurg-2020-017042 | PMID 33526479 Get It

Background Over the past several years there has been increased interest in the use of the Sofia aspiration system (MicroVention, Tustin, California) as a primary aspiration catheter. Objective To perform a multicenter retrospective study examining the efficacy of the Sofia aspiration catheter as a standalone aspiration treatment for large vessel occlusion. Methods Consecutive cases in which the Sofia catheter was used for aspiration thrombectomy for large vessel occlusion were included. Exclusion criteria were the following: (1) Sofia not used for first pass, and (2) a stent retriever used as an adjunct on the first pass. The primary outcome of the study was first pass recanalization (Thrombolysis in Cerebral Infarction (TICI) 2c/3). Secondary outcomes included first pass TICI 2b/3, crossover to other thrombectomy devices, number of passes, time from puncture to recanalization, and complications. Results 323 patients were included. First pass TICI 2c/3 was achieved in 49.8% of cases (161/323). First pass TICI 2b/3 was achieved in 69.7% (225/323) of cases. 74.8% had TICI 2b/3 with the Sofia alone. Crossover to other thrombectomy devices occurred in 29.1% of cases (94/323). The median number of passes was 1 (IQR=1–3). Median time from puncture to recanalization was 26 min (IQR=17–45). Procedure related complications occurred in 3.1% (10/323) of cases. Conclusion Our study highlights the potential advantage of the Sofia aspiration catheter for primary aspiration thrombectomy in acute ischemic stroke. High rates of first pass recanalization with low crossover rates to other thrombectomy devices were achieved. Median procedure time was low, as were procedural complications.
Endovascular Treatment of Aneurysms Using Flow-Diversion Embolization: 2-Dimensional Operative Video
Cavalcanti, Daniel D. , Nelson, Peter Kim , Raz, Eytan , Shapiro, Maksim , Nossek, Erez , Tanweer, Omar , Riina, Howard A. , Bain, Mark, Bendock, Bernard, Boulos, Alan S. , Fessler, Richard D., Guterman, Lee R., Hoit, Daniel , Nelson, L Hopkins, Howington, Jay U., James, Robert F. , Jankowitz, Brian T. , Kan, Peter , Khalessi, Alex A, Kim, Louis J. , Langer, David J. , Levitt, Michael , Mack, William J. , Mericle, Robert A., Ogilvy, Chris, Replogle, Robert, Saugaveau, Eric, Schirmer, Clemens M. , Spiotta, Alex, Sultan, Ali, Raymond, Turner, Welch, Babu G. , Schirmer, Clemens M , Grande, Andrew Walker , Hanel, Ricardó A. , Kim, Louis J. , Lanzino, Giuseppe , Levitt, Michael, Lopes, Demetrius K. , Mocco, J , Rodriguez, Rafael, Siddiqui, Adnan H. , Thomas, Ajith J , White, Jonathan Samuel

Mayo Clinic

Operative Neurosurgery | January 31, 2021 | Volume: 20 | Issue: 4 | Pages: E284-E285

10.1093/ons/opaa462 | PMID 33517417 Get It

Abstract Initially developed for large and giant wide-necked aneurysms of the internal carotid artery, flow diverter devices are now used in almost every location safely and with effectiveness. 1-5 This video demonstrates a unique case of a giant aneurysm of the right petrous internal carotid artery in a 20-yr-old patient. This is an extremely rare location, and most of patients are asymptomatic. 3-6 Signs of compression of the seventh and eight cranial nerves can be present and even Horner syndrome and lower cranial nerves neuropathies. Nevertheless, rupture can lead to epistaxis and otorrhagia, and ultimately to hemorrhagic shock. The patient in the current report was otherwise healthy but presented with lightheadedness and dizziness for 10 d. The patient consented to the procedure. There was no history of major trauma or head and neck infection. A transradial endovascular flow diversion embolization of a giant aneurysm of the petrous internal carotid artery is herein demonstrated in a stepwise manner. A triaxial system was used to deploy 3 overlapping devices. Concepts of J-wire technique, multiple coverage, 1 and the so-called weld technique are emphasized. The role of adjunctive coiling and main reasons for failure are also discussed. 7,8 Brief cases of flow diversion embolization of aneurysms of different morphologies at different locations are used to highlight the importance of assessing vessel wall apposition and follow-up imaging.